Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ANRO vs PTN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANRO Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

ANRO Overall Winner 6-Pillar Tally: ANRO 3 – 3 PTN Matrix Metrics: ANRO 7 – 3 PTN

As of Nov 16, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Palatin Technologies, Inc. (PTN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ANRO carries a Unified Composite Score of 30.5/100 (SELL) at $27.12 (N/M Forward P/E, 0.0% operating margin), whereas PTN carries 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin).

  • Composite vs. Pillar Nuance: While PTN currently prints a higher short-term Unified Composite Score (31.5/100 SELL vs. ANRO 30.5/100 SELL), ANRO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -65.7% operating margin) and revenue trajectory (+0.0% vs. -80.1% YoY).
  • Defensive Composite Rating Caution: Although ANRO compares more favorably head-to-head, both ANRO (30.5/100 SELL) and PTN (31.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 54.3); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANRO vs PTN
ANRO NYSE Head-to-Head Winner
Alto Neuroscience Inc.
Pharmaceutical Preparations
$27.12
-8.19% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.95β · 90% Vol
Unified Composite Score
30.5 / 100 SELL
Tech 5.0 Fund 32.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.3 · SMA20: $24.83 · SMA50: $26.20
PTN US Equity
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
TTM Revenue $13M
Forward P/E 42.9x
Beta / 30D Vol 0.87β · 106% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $5.72 · SMA50: $8.07

6-Pillar Scorecard Institutional Category Breakdown (ANRO 3 – 3 PTN)

Columns: Metric · ANRO · PTN
1. Valuation Multiples PTN
Forward P/E N/M 42.9x
Trailing P/E N/M 42.9x
PEG Ratio N/M 1.62x
EV / Revenue N/M 0.1x
2. Growth & Scale ANRO
Revenue Growth (YoY) +0.0% -80.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $13M
Market Cap $1.2B $11.1M
3. Profitability & Quality ANRO
Gross Margin N/A 6.2%
Operating Margin 0.0% -65.7%
Net Profit Margin 0.0% -63.5%
Return on Equity (ROE) -46.7% -877.5%
4. Balance Sheet & Cash Flow PTN
Cash Generation (TTM) -$80M -$15M
Cash Flow Margin N/A -113.6%
Net Cash / Leverage $301M Net Cash $9.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANRO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 79.4% (8th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat PTN
OpEx & R&D Intensity N/A 71.9% of Rev ($9.5M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANRO (7) vs PTN (3)
Institutional Metric ANRO PTN Criterion Row Edge
Market Capitalization
Scale
$1.2B $11.1M Larger Scale ANRO
Trailing P/E Ratio
Valuation
N/M 42.9x Lower Multiple PTN
Forward P/E Ratio
Valuation
N/M 42.9x Lower Multiple PTN
Revenue Growth (YoY)
Growth
+0.0% -80.1% Higher Growth ANRO
Operating Margin (TTM)
Profitability
0.0% -65.7% Higher Margin ANRO
Net Profit Margin
Profitability
0.0% -63.5% Higher Margin ANRO
Return on Equity (ROE)
Capital Efficiency
-46.7% -877.5% Higher ROE ANRO
52-Week Range Position
Momentum
61% ($11–$37) 6% ($5–$31) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
1.95β · 90% Vol 0.87β · 106% Vol Lower Realized Risk ANRO
Unified Institutional Score
Composite Signal
30.5 / 100 (SELL) 31.5 / 100 (SELL) Higher Composite PTN
Trailing 12M Revenue (USD)
Operating Scale
N/A $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 6.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.62x PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$80M ($301M Net Cash) -$15M ($9.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANRO +21.87 pp
ANRO: +23.61% · PTN: +1.74%
3M Horizon ANRO +21.18 pp
ANRO: -20.54% · PTN: -41.72%
6M Horizon ANRO +84.21 pp
ANRO: +24.4% · PTN: -59.81%
1Y Horizon ANRO +182.23 pp
ANRO: +138.94% · PTN: -43.29%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs PTN. Trailing 12-month operating profitability (ANRO 0.0% vs PTN -65.7%) and valuation multiples (ANRO N/M vs PTN 42.9x Forward P/E) are benchmarked directly in Pillar 4 below.

ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M
PTN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin6.2%
Op. Margin-65.7%
ROE / Fwd P/E-877.5% · 42.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANRO BREAKDOWN
57d in phase · OBV ACCUMULATION
Current IV 79.4%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PTN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PTN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment 71.9% of Rev ($9.5M)
90D Engineering Disclosures 0 Published

Investor FAQ ANRO vs PTN Key Questions & Quantitative Answers

As of Nov 16, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Palatin Technologies, Inc. (PTN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ANRO carries a Unified Composite Score of 30.5/100 (SELL) at $27.12 (N/M Forward P/E, 0.0% operating margin), whereas PTN carries 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin). Composite vs. Pillar Nuance: While PTN currently prints a higher short-term Unified Composite Score (31.5/100 SELL vs. ANRO 30.5/100 SELL), ANRO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -65.7% operating margin) and revenue trajectory (+0.0% vs. -80.1% YoY). Defensive Composite Rating Caution: Although ANRO compares more favorably head-to-head, both ANRO (30.5/100 SELL) and PTN (31.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 54.3); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANRO leads the Growth & Scale pillar: ANRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PTN at -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin). On trailing 12-month operating scale, ANRO generates N/A in USD-normalized revenue versus $13M for PTN. In operating R&D and SG&A reinvestment, ANRO deploys N/A (0 90-day corporate R&D disclosures) versus 71.9% of Rev ($9.5M) (0 disclosures) for PTN.

PTN screens cheaper on headline valuation multiples. ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANRO (-46.7% ROE) versus PTN (-877.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.95β · 90% Vol realized risk). By comparison, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.